Neuraxis

Neuraxis EBITDA per Employee

The EBITDA per Employee of Neuraxis (NRXS) as of Nov 22, 2026 is -460,582.82 USD. In the previous year, EBITDA per Employee was -453,527.18 USD — a change of 1.56% (lower).

EBITDA per Employee

-460,582.82USD

YoY

1.56%

Last updated:

EBITDA per Employee of Neuraxis is 2025 -460,582.82 USD. EBITDA per Employee of Neuraxis was 2024 -453,527.18 USD. It decreases by 1.56% lower compared to the previous year.

The Neuraxis EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2020
-242,396.35 USD
Jan 1, 2021
-175,947.29 USD
Jan 1, 2022
-256,615.29 USD
Jan 1, 2023
-392,029.12 USD
Jan 1, 2024
-453,527.18 USD
Jan 1, 2025
-460,582.82 USD
The Neuraxis EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-460,582.82USD+1.56%
-453,527.18USD+15.69%
-392,029.12USD+52.77%
-256,615.29USD+45.85%
-175,947.29USD-27.41%
-242,396.35USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

EBITDA per Employee of Neuraxis is -460,582.82 USD in 2025.

EBITDA per Employee of Neuraxis changed from -453,527.18 USD to -460,582.82 USD, representing a 1.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Neuraxis since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Neuraxis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Neuraxis

All Key Metrics — Neuraxis